Roche Holding AG (RHHBY)
| Previous close | 38.30 |
| Open | 38.40 |
| Bid | 38.44 x 40000 |
| Ask | 38.43 x 40000 |
| Day's range | 38.36 - 38.66 |
| 52-week range | 29.20 - 42.43 |
| Volume | |
| Avg. volume | 1,649,526 |
| Market cap | 249.643B |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | 19.80 |
| EPS (TTM) | 1.94 |
| Earnings date | 25 July 2024 |
| Forward dividend & yield | 1.35 (3.51%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 44.34 |
GlobeNewswireRoche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY
The new VENTANA CLDN18 (43-14A) RxDx Assay helps fulfil an unmet medical need by enabling clinicians to identify patients with gastric or gastroesophageal junction (GEJ) cancer who may benefit from a targeted treatment option. CLDN18.2 is an emerging biomarker in gastric and GEJ cancers and helps predict the likelihood of response to targeted therapy.As the leader in companion diagnostics, Roche continues to build on its commitment to improve personalised healthcare to enable better patient outc
- GuruFocus.com
OmniAb Inc (OABI) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Partnerships ...
OmniAb Inc (OABI) reports increased revenue and new partnerships, while navigating program discontinuations and competitive pressures.
GuruFocus.comLineage Cell Therapeutics Inc (LCTX) Q2 2024 Earnings Call Highlights: Strategic Alliances and ...
Despite a challenging biotech market, Lineage Cell Therapeutics Inc (LCTX) strengthens partnerships and maintains a strong cash position to support future growth.
